These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1407898)

  • 1. Should women with familial ovarian cancer undergo prophylactic oophorectomy?
    Kerlikowske K; Brown JS; Grady DG
    Obstet Gynecol; 1992 Oct; 80(4):700-7. PubMed ID: 1407898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of prophylactic oophorectomy in cancer prevention.
    Averette HE; Nguyen HN
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S38-41. PubMed ID: 7835808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Attitudes toward prophylactic oophorectomy and screening utilization in women at increased risk of developing hereditary breast/ovarian cancer.
    Meiser B; Butow P; Barratt A; Friedlander M; Gattas M; Kirk J; Suthers G; Walpole I; Tucker K
    Gynecol Oncol; 1999 Oct; 75(1):122-9. PubMed ID: 10502438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial ovarian cancer.
    Elit L
    Can Fam Physician; 2001 Apr; 47():778-84. PubMed ID: 11340759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing hereditary ovarian cancer.
    Mourits MJ; de Bock GH
    Maturitas; 2009 Nov; 64(3):172-6. PubMed ID: 19811881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Familial ovarian cancer syndrome].
    Bösze P
    Orv Hetil; 1994 Feb; 135(9):459-64. PubMed ID: 8139849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role and place of the prophilactic oophorectomy].
    Zlatkov V; Kostova P
    Akush Ginekol (Sofiia); 2004; 43 Suppl 4():43-8. PubMed ID: 15673014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic oophorectomy in inherited breast/ovarian cancer families.
    Struewing JP; Watson P; Easton DF; Ponder BA; Lynch HT; Tucker MA
    J Natl Cancer Inst Monogr; 1995; (17):33-5. PubMed ID: 8573450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemoprevention and prophylactic surgery in ovarian carcinoma].
    Deffieux X; Touboul C; Uzan C; Faivre E; Frydman R; Fernandez H; Morice P
    J Gynecol Obstet Biol Reprod (Paris); 2007 Dec; 36(8):756-63. PubMed ID: 17719183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Aiduk C
    Gynecol Oncol; 1997 Jul; 66(1):103-7. PubMed ID: 9234929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic oophorectomy and ovarian cancer surveillance. Patient perceptions and satisfaction.
    Swisher EM; Babb S; Whelan A; Mutch DG; Rader JS
    J Reprod Med; 2001 Feb; 46(2):87-94. PubMed ID: 11255821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis.
    Modugno F; Ness RB; Allen GO; Schildkraut JM; Davis FG; Goodman MT
    Am J Obstet Gynecol; 2004 Sep; 191(3):733-40. PubMed ID: 15467532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of family history on ovarian cancer risk. The Utah Population Database.
    Kerber RA; Slattery ML
    Arch Intern Med; 1995 May; 155(9):905-12. PubMed ID: 7726698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer.
    Gross TP; Schlesselman JJ
    Obstet Gynecol; 1994 Mar; 83(3):419-24. PubMed ID: 8127536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis.
    Armstrong K; Schwartz JS; Randall T; Rubin SC; Weber B
    J Clin Oncol; 2004 Mar; 22(6):1045-54. PubMed ID: 14981106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.